S. M. Saker Billah

S. M. Saker Billah

Auto-generated profile, based on publicly available information

S. M. Saker Billah

Department of Chemistry, National University, Gazipur, Bangladesh

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Annals of Human Biology
Verified
Journal Article
Open access
SBSm Faysal Bellah
Sm Faysal Bellah
ASAbdus Salam
Abdus Salam
SBS. M. Saker Billah
S. M. Saker Billah
RKRezaul Karim
Rezaul Karim
CYP3A4 and CYP3A5 are biologically potential genes responsible for prostate cancer.We aimed to analyse the expression and association of CYP3A4 and CYP3A5 genes in prostate cancer.Web-based bioinfo...

1 October 2016 in Human Pathology
Verified
Journal Article
Closed access
AQAndres E. Quesada
Andres E. Quesada
HLHuifei Liu
Huifei Liu
RMRoberto Nicolas Miranda
Roberto Nicolas Miranda
NGNatalia Golardi
Natalia Golardi
SBShahreen Billah
Shahreen Billah
JJJesse Manuel Jaso
Jesse Manuel Jaso

1 January 2025 in International Journal of Breast Cancer
Verified
Journal Article
Open access
SBSm Faysal Bellah
Sm Faysal Bellah
AHAlim Hossen
Alim Hossen
SBS. M. Saker Billah
S. M. Saker Billah
NINur Islam
Nur Islam
Background: Breast cancer is a leading cause of cancer‐related morbidity and mortality in women worldwide. Among its subtypes, triple‐negative breast cancer (TNBC) poses the greatest therapeutic challenge due to its aggressive nature and lack of targeted treatments. Holocytochrome c synthase (HCCS), a mitochondrial enzyme essential for cytochrome c maturation, may play a pivotal role in cancer pathogenesis. Objective: This study aimed to investigate the expression profile, epigenetic regulation, immune interactions, prognostic significance, and molecular networks of HCCS across cancers, with a particular focus on breast cancer and its subtypes. Methods: Publicly available datasets and bioinformatics tools were employed to analyze HCCS expression, methylation, survival outcomes, immune infiltration, and interaction networks. Expression and clinical outcomes were examined using TCGA, while methylation and expression patterns were assessed via UALCAN and TNMplot. Survival analyses were performed using Kaplan–Meier Plotter, and immune infiltration was evaluated with TIMER2.0. Protein–protein interaction networks were generated with STRING, and functional enrichment was conducted through g:Profiler. Key findings were validated in independent breast cancer cohorts from GEO and the GOBO platform. Results: HCCS was significantly overexpressed in multiple cancers, with the highest upregulation observed in breast cancer, particularly TNBC. Hypomethylation of the HCCS promoter was associated with increased expression. High HCCS expression correlated with poorer relapse‐free survival and greater immune infiltration, including CD4 + T cells, CD8 + T cells, macrophages (M1/M2), mast cells, and regulatory T cells. Protein–protein interaction analysis revealed HCCS‐associated genes enriched in mitochondrial and apoptotic pathways. Validation across independent datasets consistently supported the association of elevated HCCS expression with poor prognosis in breast cancer. Conclusion: This integrated bioinformatics analysis highlights HCCS as a potential prognostic biomarker and therapeutic target in breast cancer, particularly in TNBC, although further experimental validation is required before clinical application.

26 March 2026 in Cancer Biomarkers
Verified
Journal Article
Open access
SBSm Faysal Bellah
Sm Faysal Bellah
AHAlim Hossen
Alim Hossen
SBS.M. Saker Billah
S.M. Saker Billah
Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Holocytochrome c synthase (HCCS), a mitochondrial enzyme involved in apoptosis and energy metabolism, has been implicated in tumorigenesis; however, its role in lung cancer is not well defined. Aim: This study aimed to elucidate the prognostic and therapeutic potential of HCCS in lung cancer through integrative bioinformatics analyses. Methods: Transcriptomic, methylation, and clinical data from TCGA were analyzed using TNMplot, UALCAN, and TIMER2.0 to evaluate HCCS expression, promoter methylation, immune infiltration, and prognostic relevance in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Meta-analysis of 18 independent cohorts from LUNG CANCER EXPLORER and four GEO datasets validated expression patterns, while Kaplan–Meier analysis assessed survival outcomes. Results: HCCS was significantly upregulated in LUAD and LUSC and showed promoter hypermethylation in LUAD. Meta-analysis and external validation confirmed its overexpression. Patients with low HCCS expression exhibited poorer overall survival, suggesting a potential tumor-suppressive effect. HCCS expression positively correlated with immune cell infiltration and co-expressed genes enriched in mitochondrial and apoptotic pathways. Conclusion: HCCS may serve as a prognostic and therapeutic biomarker in lung cancer, linking mitochondrial regulation, epigenetic modification, and immune interactions.

1 December 2017 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Open access
NHNafiseh Hashemi
Nafiseh Hashemi
SBShahreen Billah
Shahreen Billah
CCChristian P. Conderman
Christian P. Conderman
IAIbrahim Alava
Ibrahim Alava
ESEmilio P. Supsupin
Emilio P. Supsupin
OAOre-Ofe O. Adesina
Ore-Ofe O. Adesina